JOIN THE BATTLE. Beat Rare Cancers.
Helping Researchers Crack the Cancer Nut
Approximately 50% of all cancer patients are fighting a rare cancer. Yet, the rarity of each cancer limits the interest of pharmaceutical companies and other funding organizations from sponsoring research on these diseases. This limits the treatment options available for our patients and increases our dependence on philanthropy to support lifesaving research for these diseases.
The Nutcrackers raise funds specifically for germ cell tumor research at MSK. These cancers include both testicular and ovarian cancers as well as more rare head and neck presentations. These cancers, like all rare cancers, disproportionately affect the young and testicular cancer is the most common cancer among men aged 21-39.
The Nutcrackers team has a lot of testicular cancer patients riding including many patients of Dr. Darren Feldman who is a clinical researcher at MSK and a recipient of Cycle funds. Two of those patients and Nutcracker leaders are Jay Erickson and Tom Berenberg. Dr. Feldman writes:
Both Jay and Tom participated in clinical trials at Memorial Sloan Kettering that wouldn’t have been possible without philanthropic funding. They were fortunate enough to get into remission but others have been less fortunate, some of whom didn’t have the same clinical trial opportunities that Jay and Tom had. I carry the memories of these young men and women with me every day and am inspired by them as well as Jay and Tom to continue working tirelessly until every patient with this disease can be cured.
100% of every dollar funds innovative studies and clinical trials led by Memorial Sloan Kettering Cancer Center (MSK). Discoveries made by MSK revolutionize how cancer is diagnosed and treated, benefitting patients everywhere.
Thank you for your support and for being on the front lines!
If you think this page contains objectionable content, please inform the system administrator.